By winning New York Dx certification, Ariosa gains a valuable marketing tool

Ariosa's Harmony prenatal test--Courtesy of Ariosa Diagnostics

Ariosa Diagnostics won certification from the New York Department of Health's Division of Laboratory Quality Certification to begin selling its Harmony prenatal and reporting test results to New York healthcare providers. That's a big step in what is now the California company's second year aggressively trying to grow its market for the test. Ariosa exists in a reality where diagnostic companies often struggle to make an impact in the marketplace after developing a test, considering that providers don't often shift easily from current standards of care. Additionally, both federal and state reimbursement, as well as a myriad of state regulations, can be hard to obtain and navigate, respectively. New York's laboratory quality standards are quite rigorous, so the milestone ends up being an advertising tool as Ariosa pursues further growth and seeks more customers. Ariosa's other rivals include Sequenom ($SQNM), Natera and Illumina's ($ILMN) Verinata Health. More

Suggested Articles

Tangen Biosciences, developers of cheap and portable molecular diagnostics for outside the lab, has raised $9 million to kick off its VC efforts.

Targeting CA19-9, a biomarker that's been used to assess pancreatic disease burden, may help treat pancreatic cancer, scientists found.

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.